US STOCK
HALO Stock Analysis
US stocks · market data · technical indicators
Halozyme Therapeutics, Inc.
HALOUS stocksQuote delayed 15 min
9/11 下午08:34 updated
$107.00
-0.39-0.36%
Open
$106.93
High
$107.95
Low
$106.36
Volume
148.77萬
HALO price history
+6.29%Open
100.67
Latest
107.00
High
110.76
Low
98.66
Average
106.70
Advertisement
AI Composite Technical Analysis
BetaFormula: fundamentals (40%) + technical indicators (30%) + market sentiment (30%)
AI Score60
Score range 0–100; a higher score indicates a stronger buy signal
Market Status
HoldCurrent Price$107
Target Price$117.7
Change %-0.36%
Institutional
Net Buying
Foreign Ownership
Reducing
Market Heat
Cautious
Fundamentals (US)
P/E Ratio
31.51x
ROE
173.67%
P/B Ratio
85.35x
Dividend Yield
--
Market Insight
The score sits in neutral territory (60/100). Waiting for a clearer signal may be warranted. Return on equity of 173.67% indicates solid profitability. The target price implies roughly 10.00% upside.
This analysis is for reference only and does not constitute investment advice. Investing carries risk; educational content only.
Financial snapshot
HALO - Halozyme Therapeutics, Inc.
EPS
3.41USD
Forward EPS
10.39USD
P/E
31.51x
Forward P/E
10.34x
P/B
85.35x
ROE
173.67%
ROA
25.49%
Operating margin
59.80%
Profit margin
24.86%
Revenue growth
47.70%
Earnings growth
42.90%
Dividend yield
--
Financial statements
| 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|---|
| Revenue | $481.00M | $376.71M | $451.77M | $354.26M | $325.72M |
| Gross profit | $401.83M | $297.47M | $373.00M | $299.02M | $279.36M |
| Operating income | $287.65M | $184.52M | $240.70M | $217.92M | $202.44M |
| Net income | $229.91M | $150.05M | -$141.59M | $175.22M | $165.16M |
| Basic EPS | 1.96 | 1.27 | -1.20 | 1.49 | 1.36 |
| Diluted EPS | 1.90 | 1.22 | -1.20 | 1.43 | 1.33 |
Estimates vs actuals
Next earnings
2026-11-02
EPS estimate
2.29
Revenue estimate
$484.32M
Last surprise
+25.53%
| Date | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-11-02 | 2.29 | Not reported | — |
| 2026-08-06 | 1.82 | 2.28 | +25.53% |
| 2026-05-11 | 1.52 | 1.60 | +5.26% |
| 2026-02-17 | 2.20 | -0.24 | -110.92% |
| 2025-11-03 | 1.63 | 1.72 | +5.51% |
| 2025-08-05 | 1.27 | 1.54 | +21.45% |
| 2025-05-06 | 0.95 | 1.11 | +17.14% |
| 2025-02-18 | 1.16 | 1.26 | +8.73% |
| 2024-10-31 | 1.00 | 1.27 | +27.05% |
| 2024-08-06 | 0.76 | 0.91 | +20.10% |
| 2024-05-07 | 0.70 | 0.79 | +13.57% |
| 2024-02-20 | 0.83 | 0.82 | -1.44% |
Institutional holders
| Institution | Quarter | Value held | Portfolio weight |
|---|---|---|---|
| BlackRock Inc. | 2024-06-30 | $922.6M | 0.02% |
| VANGUARD GROUP INC | 2025-12-31 | $778.5M | 0.01% |
| STATE STREET CORP | 2026-06-30 | $405.4M | 0.01% |
| TWO SIGMA INVESTMENTS, LP | 2026-06-30 | $129.4M | 0.09% |
| RENAISSANCE TECHNOLOGIES LLC | 2026-06-30 | $37.5M | 0.05% |
| Bridgewater Associates, LP | 2026-06-30 | $36.3M | 0.15% |
| CITADEL ADVISORS LLC | 2026-06-30 | $22.6M | 0.00% |
13F quarterly filings. Reporting periods differ by institution; value and weight reflect each institution's own latest quarter.
Analyst ratings
Mean target
$99.56
Target range
$70.00 – $115.00
Implied upside
-7.35%
Strong buy
2
Buy
5
Hold
2
Sell
0
Strong sell
0
Advertisement